Aurora receives expanded cultivation and unique research licenses for german facility

Nasdaq | tsx: acb company's long-standing investment in the region continues with enhanced local production and domestic cultivar research edmonton, ab , july 25, 2024 /prnewswire/ - aurora cannabis inc. (the "company" or "aurora") (nasdaq: acb) (tsx: acb), a leading canadian-based global medical cannabis company, has been granted two licenses by the federal institute for drugs and medical devices (bfarm) under germany's new medical cannabis act (medcang). aurora's license grants the company continued domestic cultivation, which has been underway for two years now.
ACB Ratings Summary
ACB Quant Ranking